Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Novacyt de volgende biotech raket!
Volgen
ik zie niet iets waar ik opgewonden van zou moeten worden
Is gewoon ruk en ze vliegen er ook uit bij mij
Cijfers waren al lang bekend, het ging om de outlook. Die is positief.
Cijfers zijn niet onaardig, het is een bedrijf met heel wat potentieel. De pijplijn ziet er ook goed uit.
Good results but Invest Securities reducing their target price to €1.24. Company is aiming "to move into EBITDA profitable trading during the year in order to become cashflow positive at the operating level." So indicating there will still be a net loss for the year. Also "During 2018, the group will continue to build on the organic sales progress made in 2017 and is evaluating the potential for further acquisitions . and how would that be paid for??? So good organic growth and potential for more by acquisitions. if this is paid by issuing new shares then of course you have a dilution effect. Evenually the acquired company brings "growth" and also Novacyt might itself be looked at by potential predators. THe 2017 loss also includes one-off costs sucha s the kisting on AIM in London and moving to new offices. One to keep for the long term if this growth continues and management can bring it around to profitability.
Afscheid genomen van Novacyt... overstapje gemaakt naar Europlasma, voor de dobbel ;-)
$4m debt facility for acquisition... Something will happen in Junewww.businesswire.com/news/home/201805...
Press Release: Novacyt Launches New Product in Infectious Mononucleosis Press Release: Novacyt Launches New Product in Infectious Mononucleosis Novacyt Launches New Product in Infectious Mononucleosis First in a series of new product launches in infectious diseases PARIS & CAMBERLEY, England--(BUSINESS WIRE)--June 05, 2018-- Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its protein diagnostics division, Lab21 Products (Lab21), has launched a new product for the diagnosis of infectious mononucleosis (IM), also known as glandular fever. PathFlow(TM) Mononucleosis is a qualitative lateral flow immunoassay for the detection of IM antibodies in the blood. IM is frequently misdiagnosed as a bacterial infection, streptococcal pharyngitis, due to common clinical presentation of the diseases at onset. IM is, however, caused by the Epstein--Barr virus (EBV) and, as a virus, IM does not respond to antibiotic treatment. PathFlow(TM) Mononucleosis provides a rapid and effective differential diagnosis to patients with IM over streptococcal pharyngitis. PathFlow(TM) Mononucleosis also facilitates antibiotic stewardship by ensuring antibiotics are not offered to patients owing to a misdiagnosis and helping to address the global issue of antibiotic resistance. IM is a global disease affecting both sexes equally(1) , which is typically observed in 60-100 per 100,000 people(2) . EBV antibodies are detected in 50% of children by 5 years of age(3) . Although the market for IM testing is relatively small it is an important niche infectious disease market and it is expected that PathFow(TM) will give clinicians a quick and reliable product to help manage their patients. The launch of PathFlow(TM) Mononucleosis is the first product in a series of high quality, lateral flow immunoassays, which will form part of Novacyt´s growing catalogue of rapid infectious disease diagnostics and aid Lab21´s position as a leader in microbial diagnostic kits. Branded under the name PathFlow(TM), these products will utilise rapid lateral flow technology, with a focus on patient pathways and improving clinical outcomes. Lab21 plans to launch a number of new products for common winter associated diseases in time for the winter peak in 2018. Graham Mullis, Group CEO of Novacyt, commented: "Lab21 Products has significant experience of developing rapid and reliable diagnostic solutions for infectious diseases. The launch of PathFlow(TM) Mononucleosis, the first product in the PathFlow(TM) product family, demonstrates our continued commitment to the R&D-led growth of our overall growth strategy. This exciting new range of diagnostic test kits enhances our new product pipeline, with a number of additional launches expected during 2018, and strengthens our position in the rapidly growing infectious disease market."
Ponzi heeft een nieuw artikel: De laatste weken ben ik bezig geweest om Novacyt te bombarderen met mails over de communicatie, zeg maar het gebrek aan communicatie. Ik heb het hier al vaker over gehad. Maar ik krijg wel het gevoel dat ik iets voor elkaar heb gekregen en dat men anders over het PR beleid is gaan nadenken. Dit heb ik niet alleen gedaan. Ook een andere Nederlandse trader heeft goede contacten en samen proberen we de CEO te overtuigen dat ze echt meer aan de PR moeten doen. Vorige week was er eindelijk dan een “nieuwtje” en vandaag kwam het verslag van de AVA. lees de rest op ponzi.nl/novacyt-stilte-voor-de-storm/
er komt beweging in de koers
Het personeel heeft er ook aan herinnerd ons het contrast tussen de cijfers verbetering (toename van de omzet, ebida netto verbetering te verhogen, ontwikkeling heeft internationale ) en de markt die geen rekening lijkt te houden met deze ontwikkelingen in de aandelenkoers. De hoop van het management met betrekking tot de aandelenkoers op de lange termijn zou zijn dat de prijs zou moeten terugkeren naar ten minste driemaal de huidige prijs over een periode van twee, drie jaar. Dit blijft natuurlijk een “wens”. Met betrekking tot het feit dat de koers lijkt te zijn “knie” een bodemprijs, ondanks het goede nieuws van het begin van het jaar, de leiders geloven niet dat het geval te zijn.
Idd vandaag ingestapt, en nu doorzetten aub
Novacyt kondigt overname van infectieziektebedrijf aan bij Omega Diagnostics
Novacyt is ook niet vooruit te branden, vanmorgen als een speer naar 0.724 en nu weer een blok in de laat van 101.000 op 0.70
Press Release: Novacyt Announces Acquisition of Infectious Disease Business from Omega Diagnostics Press Release: Novacyt Announces Acquisition of Infectious Disease Business from Omega Diagnostics Novacyt Announces Acquisition of Infectious Disease Business from Omega Diagnostics Accelerating profitability by expanding the Lab21 business with complimentary products PARIS & CAMBERLEY, England--(BUSINESS WIRE)--June 28, 2018-- Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that its protein diagnostics division, Lab21 Products (Lab21), has unconditionally entered into an asset purchase agreement to acquire the Infectious Disease (ID) business from Omega Diagnostics Ltd (AIM: ODX, "Omega Diagnostics"), for an initial consideration of GBP1.8 million, up to GBP2.175 million in total, subject to the achievement of certain milestones (the "Acquisition"). Highlights -- Highly complementary product range increases offering and global reach of Lab21, opening new sales channel opportunities, particularly on the African continent -- Adds GBP2.49 million of annual sales and positive operational cash flows -- Acquisition is expected to be immediately earnings accretive in the second-half of 2018 -- Cost synergies immediately anticipated as a result of leveraging existing commercial infrastructure within Novacyt, leading to an operating margin expansion for the ID business -- Revenue synergies targeted from 2019 -- Additional manufacturing through the purchase of certain assets based in Axminster, UK providing a more competitive manufacturing position and increasing production capability -- Transaction multiple of 0.9x sales (to unaudited financial year end 31 March 2018), pre-realisation of any expected synergies Infectious Disease Business The ID business specialises in the manufacture of a range of diagnostic kits, in particular for syphilis and febrile antigens, as well as a range of latex serology tests for rheumatoid factor, C-reactive protein, antistreptolysin and systemic lupus erythematosus. Lab21 will assume the commercial rights to five core registered brands, which comprise enzyme immunoassays microtitre plates, latex agglutination, fluorescence and rapid lateral flow tests. The brands include; Immutrep, Avitex, Micropath, Pathozyme and other smaller brands including Betatex, Avistrep, Avistaph and Virotect. In addition, Lab21 will be granted a time-limited licence for the use of the name Visitect for certain lateral flow tests excluding Omega Diagnostics´ Visitect CD4 assets, all of which will remain with Omega. Unaudited results for twelve months to 31 March 2018 showed sales of the Omega ID business of GBP2.49 million and EBITDA profitability of GBP310,000. Novacyt expects to see similar sales in the first twelve months of ownership and material cost synergies are anticipated immediately as a result of leveraging existing commercial and manufacturing infrastructure within Novacyt, leading to operating margin expansion. Revenue synergies are expected over the subsequent twelve months. Terms of the Agreement Under the terms of the asset purchase agreement, the total consideration, to be fully satisfied through cash consideration, will be up to GBP2.175 million subject to performance, comprising: (i) GBP1.8 million upon completion, (ii) GBP175,000 paid after twelve months upon completion of technology transfer and, (iii) GBP200,000 paid upon the successful accreditation of the Axminster, UK production facility to certain standards. The full consideration of GBP2.175 million if paid represents a modest multiple of 0.9x year sales. The asset includes the customers, suppliers, trademarks, contracts, stocks, technical files and know-how in order to manufacture, distribute and market the ID assets. There will also be some manufacturing equipment which will come with a manufacturing facility, though fixed assets will be a small part of the purchase. Through TUPE, Novacyt expects to transfer two Omega employees only at this time. No management or directors will come across with the Acquisition. Omega Diagnostics will assist Novacyt with the transfer of manufacturing from its Alva, Scotland site which is expected to take six months and will provide any technical assistance for up to twelve months. All sales orders, despatch and invoicing of the ID business unit will be undertaken by Novacyt from today. Graham Mullis, Group CEO of Novacyt, added: "I am delighted to agree terms to acquire the ID business directly from Omega Diagnostics. We have been looking to expand our Lab21 product range and the ID business is a perfect match with our current portfolio. This acquisition is expected to deliver material cost and growth synergies as we leverage the Novacyt infrastructure and integration will start immediately after completion. We continue to assess a deep pipeline of potential further acquisitions and I look forward to updating the market as we continue to deliver on our acquisitive growth objective." Colin King, CEO Omega Diagnostics, "In April we announced a strategic review of our business with a focus on VISITECT(R) CD4, Allersys and Food Intolerance products. The sale of the ID business is an important outcome of our review and we are delighted to be working with Novacyt where we expect the products and customers to be a good fit with the Lab21 Products division." The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Goed nieuws toch? Of zie ik dit verkeerd?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee